(Q34261645)

1 August 2017

title

Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration (English)

1 reference

1 August 2017

1 reference

7

R Scott McIvor

1 reference

1 August 2017

Daniel A Wolf

1

1 reference

1 August 2017

Leah R Hanson

2

1 reference

1 August 2017

Elena L Aronovich

3

1 reference

1 August 2017

Zhenhong Nan

4

1 reference

1 August 2017

Walter C Low

5

1 reference

1 August 2017

William H Frey

6

1 reference

1 August 2017

publication date

10 February 2012

1 reference

Molecular Genetics and Metabolism

1 August 2017

published in

1 reference

1 August 2017

volume

106

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

131-134

1 reference

Transnasal delivery of methotrexate to brain tumors in rats: a new strategy for brain tumor chemotherapy

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Intranasal delivery of cells to the brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Intranasal administration of the growth-compromised HSV-2 vector DeltaRR prevents kainate-induced seizures and neuronal loss in rats and mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Delivery of NGF to the brain: intranasal versus ocular administration in anti-NGF transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Intranasal delivery to the central nervous system: mechanisms and experimental considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Intranasal nerve growth factor enhances striatal neurogenesis in adult rats with focal cerebral ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.006

10.1016/J.YMGME.2012.02.006

7 January 2021

Identifiers

DOI

1 reference

1 August 2017

1 reference